Situación actual de los anticoagulantes orales de acción directa en atención primaria de España. Posicionamiento de SEMERGEN en 2023(Pag.-e 102136)

Referencias bibliográficas

• Llisterri JL, Pallarés V, Polo J, Prieto MA. Posicionamiento de SEMERGEN sobre la utilización de los anticoagulantes oralesde acción directa. Madrid. 2017. Disponible en: https://semergen.es/resources/files/biblioteca/guiaClinicas/Posicionamiento%20ACODs%20SEMERGEN.pdf Google Scholar
• J.L. Llisterri Caro, S. Cinza-Sanjurjo, J. Polo Garcia, M.A. Prieto Díaz Utilización de los anticoagulantes orales de acción directa en Atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual Semergen., 45 (2019), pp. 413-429 View PDFView articleView in ScopusGoogle Scholar
• G. Hindricks, T. Potpara, N. Dagres, E. Arbelo, J.J. Bax, C. Blomström-Lundqvist, et al., ESC Scientific Document Group 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J., 42 (2021), pp. 373-498 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• C.T. January, L.S. Wann, H. Calkins, L.Y. Chen, J.E. Cigarroa, J.C. Cleveland Jr., et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons Circulation., 140 (2019), pp. e125-e151 View in ScopusGoogle Scholar
• J. Steffel, R. Collins, M. Antz, P. Cornu, L. Desteghe, K.G. Haeusler, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation Europace., 23 (2021), pp. 1612-1676 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, E. Briët A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost., 69 (1993), pp. 236-239 View in ScopusGoogle Scholar
• V. Barrios, A. Calderón, C. Escobar, M. de la Figuera Pacientes con fibrilación auricular asistidos en consultas de atención primaria. EstudioVal-FAAP Rev Esp Cardiol., 65 (2012), pp. 47-53 View PDFView articleView in ScopusGoogle Scholar
• J.J. Gómez-Doblas, J. Muñiz, J.J.A. Martin, G. Rodríguez-Roca, J.M. Lobos, P. Awamleh, et al. Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE Rev Esp Cardiol., 67 (2014), pp. 259-269 View PDFView articleView in ScopusGoogle Scholar
• G. Lippi, F. Sanchis-Gomar, G. Cervellin Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge Int J Stroke., 16 (2021), pp. 217-221 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• C.W. Tsao, A.W. Aday, Z.I. Almarzooq, C.A.M. Anderson, P. Arora, C.L. Avery, et al. Heart Disease and Stroke Statistics — 2023 update: A report from the American Heart Association Circulation., 147 (2023), pp. e93-e621 Google Scholar
• L.J.H.J. Theunissen, J.A.A. van de Pol, van Steenbergen, H.P. Cremers, D. van Veghel, P.H. van der Voort, et al. The prognostic value of quality of life in atrial fibrillation on patient value Health Qual Life Outcomes., 21 (2023), p. 33 View at publisher This article is free to access. View in ScopusGoogle Scholar
• B.A. Steinberg, S. Kim, G.C. Fonarow, L. Thomas, J. Ansell, P.R. Kowey, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Am Heart J., 167 (2014), pp. 735-742 View at publisher Your institution provides access to this article. View in ScopusGoogle Scholar
• A. Alonso, Z. Almuwaqqat, A. Chamberlain Mortality in atrial fibrillation. Is it changing? Trends Cardiovasc Med., 31 (2021), pp. 469-473 View PDFView articleView in ScopusGoogle Scholar
• D. Pastori, P. Pignatelli, F. Angelico, A. Farcomeni, M. del Ben, T. Vicario, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: Relation to atherosclerotic risk factors Chest., 147 (2015), pp. 1644-1650 View PDFView articleCrossRefView in ScopusGoogle Scholar
• J. Masjuan-Vallejo, A. Cequier-Fillat, V. Expósito-García, C. Suárez-Fernández, I. Roldán-Rabadán, R. Frexia-Pamias, et al. Prevención del ictus en pacientes con fibrilación auricular. Mejorar la protección en la era de la COVID-19 Rev Esp Cardiol Supl., 21A (2021), pp. 9-17 Google Scholar
• J. Masjuán, J. Álvarez-Sabín, M. Blanco, A. de Felipe, A. Gil-Núñez, J. Gállego-Culleré, et al. Manejo actual del tratamiento antitrombótico en pacientes con fibrilación auricular no valvular y antecedentes de ictus o ataque isquémico transitorio Rev Neurol., 59 (2014), pp. 25-36 View in ScopusGoogle Scholar
• S. Jiang, S.P. Seslar, L.A. Sloan, R.N. Hansen Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities J Manag Care Spec Pharm., 28 (2022), pp. 1321-1330 View at publisher CrossRefView in ScopusGoogle Scholar
• E.P. Zeitler, C.J. Ronk, A. Cockerham, S. Huse, D.S. McKindley, M.H. Kim Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States Expert Rev Pharmacoecon Outcomes Res., 22 (2022), pp. 763-771 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• G.Y.H. Lip The ABC pathway: An integrated approach to improve AF management Nat Rev Cardiol., 14 (2017), pp. 627-628 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• G.F. Romiti, D. Pastori, J.M. Rivera-Caravaca, W.Y. Ding, Y.X. Gue, D. Menichelli, et al. Adherence to the ‘atrial fibrillation better care’ (ABC) pathway in patients with atrial fibrillation Thromb Haemost., 122 (2022), pp. 406-414 View at publisher This article is free to access. View in ScopusGoogle Scholar
• J. Díaz-Guzmán, R. Freixa-Pamias, J. García-Alegría, A.I. Pérez Cabeza, I. Roldán-Rabadán, B. Antolin-Fontes, et al. Epidemiología del ictus cardioembólico y su asociación con la penetración de los ACOD en España: primer estudio poblacional 2005-2018 Rev Esp Cardiol., 75 (2022), pp. 496-505 View PDFView articleView in ScopusGoogle Scholar
• A. Murphy, A. Banerjee, G. Breithardt, A.J. Camm, P. Commerford, B. Freedman, et al. The World Heart Federation roadmap for nonvalvular atrial fibrillation Glob Heart., 12 (2017), pp. 273-284 View PDFView articleCrossRefView in ScopusGoogle Scholar
• R. Pisters, D.A. Lane, F. Marin, A.J. Camm, G.Y. Lip Stroke and thromboembolism in atrial fibrillation Circ J., 76 (2012), pp. 2289-2304 View in ScopusGoogle Scholar
• F.M. Szymanski, G.Y. Lip, K.J. Filipiak, A.E. Platek, A. Hrynkiewicz-Szymanska, G. Opolski Stroke risk factors beyond the CHA(2)DS(2)-VASc score: can we improve our identification of ‘high stroke risk’ patients with atrial fibrillation? Am J Cardiol., 116 (2015), pp. 1781-1788 View PDFView articleView in ScopusGoogle Scholar
• M.A. Esteve-Pastor, V. Roldan, J.M. Rivera-Caravaca, I. Ramirez-Macias, G.Y.H. Lip, F. Marin The use of biomarkers in clinical management guidelines: A critical appraisal Thromb Haemost., 119 (2019), pp. 1901-1919 View at publisher This article is free to access. View in ScopusGoogle Scholar
• G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation Chest., 137 (2010), pp. 263-272 View PDFView articleCrossRefView in ScopusGoogle Scholar
• R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, G.Y. Lip A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey Chest., 138 (2010), pp. 1093-1100 View PDFView articleCrossRefView in ScopusGoogle Scholar
• B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, M.W. Rich, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J., 151 (2006), pp. 713-719 View PDFView articleView in ScopusGoogle Scholar
• M.C. Fang, A.S. Go, Y. Chang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study J Am Coll Cardiol., 58 (2011), pp. 395-401 View PDFView articleView in ScopusGoogle Scholar
• L. Friberg, M. Rosenqvist, G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study Eur Heart J., 33 (2012), pp. 1500-1510 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• Z. Hijazi, J. Oldgren, J. Lindback, J.H. Alexander, S.J. Connolly, J.W. Eikelboom, et al., ARISTOTLE and RE-LY Investigators The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: A derivation and validation study Lancet., 387 (2016), pp. 2302-2311 View PDFView articleView in ScopusGoogle Scholar
• S. Apostolakis, D.A. Lane, Y. Guo, H. Buller, G.Y. Lip Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study J Am Coll Cardiol., 60 (2012), pp. 861-867 View PDFView articleView in ScopusGoogle Scholar
• C. Escobar, A.J. Camm Changing paradigms: From prevention of thromboembolic events to improved survival in patients with atrial fibrillation Europace., 23 (2021), pp. 837-843 View at publisher CrossRefView in ScopusGoogle Scholar
• R.G. Hart, L.A. Pearce, M.I. Aguilar Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med., 146 (2007), pp. 857-867 View at publisher CrossRefView in ScopusGoogle Scholar
• S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, S. Golitsyn, et al. Apixaban in patients with atrial fibrillation N Engl J Med., 364 (2011), pp. 806-817 View in ScopusGoogle Scholar
• J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest., 133 (6 Suppl) (2008), pp. 160S-198S View PDFView articleCrossRefGoogle Scholar
• M.H. Umer Usman, S. Raza, S. Raza, M. Ezekowitz Advancement in antithrombotics for stroke prevention in atrial fibrillation J Interv Card Electrophysiol., 22 (2008), pp. 129-137 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• E.A. Nutescu, N.L. Shapiro, A. Chevalier New anticoagulant agents: Direct thrombin inhibitors Cardiol Clin., 26 (2008), pp. 169-187 View PDFView articleView in ScopusGoogle Scholar
• V. Barrios, J.L. Górriz Atrial fibrillation and chronic kidney disease: Focus on rivaroxaban J Comp Eff Res., 4 (2015), pp. 651-664 View at publisher CrossRefView in ScopusGoogle Scholar
• V. Barrios, C. Escobar, L. Prieto, G. Osorio, J. Polo, J.M. Lobos, et al. Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA Rev Esp Cardiol., 68 (2015), pp. 769-776 View PDFView articleView in ScopusGoogle Scholar
• S. Cinza-Sanjurjo, D. Rey-Aldana, E. Gestal-Pereira, C. Carlos Calvo- Gómez Evaluación del grado de anticoagulación de pacientes con fibrilación auricular en el ámbito de atención primaria de Galicia. Estudio ANFAGAL Rev Esp Cardiol (Engl Ed)., 68 (2015), pp. 753-760 View PDFView articleView in ScopusGoogle Scholar
• R. Alonso Roca, C.A. Figueroa Guerrero, V. Mainar de Paz, M.P. Arribas García, L. Sánchez Perruca, R. Rodríguez Barrientos, et al. Grado de control del tratamiento anticoagulante oral en los centros de Atención Primaria de la Comunidad de Madrid: Estudio CHRONOS-TAO Med Clin., 145 (2015), pp. 192-197 View PDFView articleView in ScopusGoogle Scholar
• M. Anguita, V. Bertomeu-Martinez, A. Cequier Fillat Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia del mal control y factores asociados Rev Esp Cardiol., 68 (2015), pp. 761-768 Google Scholar
• V. Bertomeu-Gonzalez, M. Anguita, J. Moreno-Arribas, A. Cequier, J. Muñiz, J. Castillo, et al. Quality of anticoagulation with vitamin K antagonists Clin Cardiol., 38 (2015), pp. 357-364 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• M.M. Contreras Muruaga, G. Reig, J. Vivancos, A. González, P. Cardona, J.M. Ramirez-Moreno, et al. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN Rev Clin Esp (Barc)., 218 (2018), pp. 327-335 View PDFView articleView in ScopusGoogle Scholar
• S. Haas, H. Ten Cate, G. Accetta, P. Angchaisuksiri, J.P. Bassand, A.J. Camm, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: A global perspective from the GARFIELD-AF Registry PLoS One., 11 (2016), p. e0164076 View at publisher CrossRefView in ScopusGoogle Scholar
• García EI, Santiñá M, Mira JJ, Carrillo Murcia I, Martin Delgado J. Atlas del mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular en España. Sociedad Española de Calidad Asistencial. Septiembre 2021. Disponible en: https://secardiologia.es/images/secciones/clinica/atlas-mal-control-anticoagulacion.pdf Google Scholar
• V. Barrios, S. Cinza-Sanjurjo, O. Gavín, I. Egocheaga, R. Burgos-Pol, J. Soto, et al. Carga y coste del mal control de la anticoagulación con antagonistas de la vitamina K en pacientes con fibrilación auricular no valvular en España Rev Esp Cardiol., 74 (2021), pp. 773-780 View PDFView articleView in ScopusGoogle Scholar
• V. Barrios, C. Escobar, A. Calderón, G.C. Rodríguez Roca, J.L. Llisterri, J. Polo García Uso del tratamiento antitrombótico según la escala CHA2DS2-VASc en los pacientes con fibrilación auricular en atención primaria Rev Esp Cardiol., 67 (2014), pp. 150-151 View PDFView articleView in ScopusGoogle Scholar
• J.C. Hsu, T.M. Maddox, K.F. Kennedy, D.F. Katz, L.N. Marzec, S.A. Lubitz, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE Registry JAMA Cardiol., 1 (2016), pp. 55-62 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• J.P. Bassand, G. Accetta, W. al Mahmeed, R. Corbalan, J. Eikelboom, D.A. Fitzmaurice, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation PLoS One., 13 (2018), p. e0191592 View at publisher CrossRefView in ScopusGoogle Scholar
• M. Mazurek, M.V. Huisman, K.J. Rothman, M. Paquette, C. Teutsch, H.C. Diener, et al. Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program Am J Med., 131 (2018), pp. 945-955 View in ScopusGoogle Scholar
• P. Apenteng, S. Virdone, J. Camm, K.A.A. Fox, J.P. Bassand, A.G.G. Turpie, et al. Determinants and clinical outcomes of patients who refused anticoagulation: Findings from the global GARFIELD-AF registry Open Heart., 10 (2023), p. e002275 View at publisher CrossRefView in ScopusGoogle Scholar
• S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med., 361 (2009), pp. 1139-1151 View in ScopusGoogle Scholar
• M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med., 365 (2011), pp. 883-891 View in ScopusGoogle Scholar
• C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med., 365 (2011), pp. 981-992 View in ScopusGoogle Scholar
• R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med., 369 (2013), pp. 2093-2104 View in ScopusGoogle Scholar
• C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials Lancet., 383 (2014), pp. 955-962 View PDFView articleView in ScopusGoogle Scholar
• V. Barrios, C. Escobar De los ensayos clínicos a la práctica clínica. Evidencias con rivaroxabán en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular Semergen., 43 (2017), pp. 222-229 View PDFView articleView in ScopusGoogle Scholar
• M. Mazurek, C. Teutsch, H.C. Diener, S.J. Dubner, J.L. Halperin, C.S. Ma, et al. Safety and effectiveness of dabigatran at 2 years: Final outcomes from phase II of the GLORIA-AF registry program Am Heart J., 218 (2019), pp. 123-127 View PDFView articleView in ScopusGoogle Scholar
• C. Escobar, V. Barrios, G.Y.H. Lip, A.N. Amin, A. Auladell-Rispau, M. Santero, et al. Effectiveness and safety of dabigatran compared to vitamin K antagonists in non-Asian patients with atrial fibrillation: A systematic review and meta-analysis Clin Drug Investig., 41 (2021), pp. 941-953 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• X.S. Li, S. Deitelzweig, A. Keshishian, M. Hamilton, R. Horblyuk, K. Gupta, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’ clinical practice. A propensity-matched analysis of 76,940 patients Thromb Haemost., 117 (2017), pp. 1072-1082 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• J.R. De Groot, T.W. Weiss, P. Kelly, P. Monteiro, J.C. Deharo, C. de Asmundis, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study Eur Heart J Cardiovasc Pharmacother., 7 (FI1) (2021), pp. f30-f39 View at publisher This article is free to access. CrossRefGoogle Scholar
• E. Rodilla, M.I. Orts-Martínez, M.A. Sanz-Caballer, M.T. Gimeno-Brosel, M.J. Arilla-Morel, I. Navarro-Gonzalo, et al. Patrones y resultados del cambio de anticoagulantes orales directos en la fibrilación auricular no valvular: experiencia en la práctica clínica en España Rev Clin Esp (Barc)., 223 (2023), pp. 340-349 View PDFView articleView in ScopusGoogle Scholar 71 C. Moret, R. Acosta-Isaac, S. Mojal, M. Corrochano, B. Jiménez, M. Plaza, et al. Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data PLoS One., 18 (2023), p. e0279297 View at publisher CrossRefView in ScopusGoogle Scholar
• M. Giner-Soriano, O. Prat-Vallverdú, D. Ouchi, C. Vilaplana-Carnerero, R. Morros Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in Catalonia Front Pharmacol., 14 (2023), p. 1110036 View in ScopusGoogle Scholar
• M. Sanmartín Fernández, M. Anguita Sánchez, F. Arribas, G. Barón-Esquivias, V. Barrios, J. Cosin-Sales, et al. Outcomes and predictive value of the 2 MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study Cardiol J., 29 (2022), pp. 601-609 View at publisher CrossRefGoogle Scholar
• B. Navarro-Almenzar, J.J. Cerezo-Manchado, F. García-Candel Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity Int J Cardiol Heart Vasc., 37 (2021), p. 100913 View PDFView articleView in ScopusGoogle Scholar
• M.R. Dalmau Llorca, C. Aguilar Martín, N. Carrasco-Querol, Z. Hernández Rojas, E. Forcadell Drago, D. Rodríguez Cumplido, et al. Gender and socioeconomic inequality in the prescription of direct oral anticoagulants in patients with non-valvular atrial fibrillation in primary care in Catalonia (Fantas-TIC Study) Int J Environ Res Public Health., 18 (2021), p. 10993 View at publisher CrossRefGoogle Scholar
• A. Charlton, X. Vidal, M. Sabaté, E. Bailarín, L.M.L. Martínez, L. Ibáñez Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation J Manag Care Spec Pharm., 27 (2021), pp. 1210-1220 View at publisher CrossRefView in ScopusGoogle Scholar
• J.M. De la Torre Hernandez, J.L. Ferreiro, R. Lopez-Palop, S. Ojeda, D. Marti, P. Avanzas, et al. Antithrombotic strategies in elderly patients with atrial fibrillation revascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry Int J Cardiol., 338 (2021), pp. 63-71 View PDFView articleView in ScopusGoogle Scholar
• M. Gabilondo, J. Loza, A. Pereda, O. Caballero, N. Zamora, A. Gorostiza, et al. Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants Hematology., 26 (2021), pp. 277-283 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• P. Domínguez-Erquicia, S. Raposeiras-Roubín, E. Abbu-Assi, M. Cespón-Fernández, D. Alonso-Rodríguez, S.J. Camacho-Freire, et al. Incidence, predictors of bleeding and prognosis of bleeding in anticoagulated nonagenarian patients with atrial fibrillation Int J Cardiol., 327 (2021), pp. 217-222 View PDFView articleView in ScopusGoogle Scholar
• M. Giner-Soriano, J. Cortes, A. Gomez-Lumbreras, O. Prat-Vallverdú, M.A. Quijada-Manuitt, R. Morros Uso y adherencia a los anticoagulantes orales en Atención Primaria en Cataluña, España: estudio de cohortes con datos procedentes de registros electrónicos de salud Aten Primaria., 52 (2020), pp. 529-538 View PDFView articleView in ScopusGoogle Scholar
• J. Rodríguez-Pardo, A. Plaza Herráiz, L. Lobato-Pérez, M. Ramírez-Torres, I. de Lorenzo, M. Alonso de Leciñana, et al. Influence of oral anticoagulation on stroke severity and outcomes: A propensity score matching case-control study J Neurol Sci., 410 (2020), p. 116685 View PDFView articleView in ScopusGoogle Scholar
• M. Anguita Sánchez, V. Bertomeu Martínez, M. Ruiz Ortiz, A. Cequier Fillat, I. Roldán Rabadán, J. Muñiz García, et al. Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes del «mundo real» con fibrilación auricular no valvular. Estudio FANTASIIA Rev Esp Cardiol., 73 (2020), pp. 14-20 View PDFView articleView in ScopusGoogle Scholar
• B. Navarro-Almenzar, J.J. Cerezo-Manchado, C. Caro-Martinez, F. García-Candel, P.J. Flores Blanco, G.E. Ruiz, et al. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase registry Curr Med Res Opin., 35 (2019), pp. 2035-2041 View at publisher CrossRefView in ScopusGoogle Scholar
• G. Zapata-Wainberg, J. Masjuan, S. Quintas, A. Ximénez-Carrillo, A. García Pastor, M. Martínez Zabaleta, et al. The neurologist's approach to cerebral infarct and transient ischaemic attack in patients receiving anticoagulant treatment for non-valvular atrial fibrillation: ANITA-FA study Eur J Neurol., 26 (2019), pp. 230-237 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• M. Cerdá, J.J. Cerezo-Manchado, E. Johansson, F. Martínez, M. Fernández, A. Varela, et al. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: Outcomes from the first observational and prospective study in a Spanish population J Comp Eff Res., 8 (2019), pp. 165-178 View at publisher CrossRefView in ScopusGoogle Scholar
• M. De la Figuera, S. Cinza, N. Marín, I. Egocheaga, M.A. Prieto Perfil clínico de pacientes con fibrilación auricular tratados con anticoagulantes orales de acción directa atendidos en atención primaria. Estudio SILVER-AP Aten Primaria., 50 (2018), pp. 359-367 View PDFView articleView in ScopusGoogle Scholar
• G.Y.H. Lip, A. Keshishian, X. Li, M. Hamilton, C. Masseria, K. Gupta, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients Stroke., 49 (2018), pp. 2933-2944 View at publisher CrossRefView in ScopusGoogle Scholar
• Y. Talmor-Barkan, N.S. Yacovzada, H. Rossman, G. Witberg, I. Kalka, R. Kornowski, et al. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial Eur Heart J Cardiovasc Pharmacother., 9 (2022), pp. 26-37 View at publisher This article is free to access. CrossRefGoogle Scholar
• B.J.R. Buckley, D.A. Lane, P. Calvert, J. Zhang, D. Gent, C.D. Mullins, et al. Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: A systematic review and meta-analysis J Clin Med., 11 (2022), p. 3788 View at publisher CrossRefView in ScopusGoogle Scholar
• F. Ma, W. Xu, J. Chen, J. Zhang Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: A systematic review and network meta-analysis Eur J Clin Pharmacol., 79 (2023), pp. 1013-1022 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• P. Archontakis-Barakakis, W. Li, D. Kalaitzoglou, L. Tzelves, A. Manolopoulos, S. Giannopoulos, et al. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies Br J Clin Pharmacol., 88 (2022), pp. 4663-4675 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• J.J. Lee, A.C.T. Ha, P. Dorian, M. Verma, S.G. Goodman, J.O. Friedrich Meta-analysis of safety and efficacy of direct oral anticoagulants versus warfarin according to time in therapeutic range in atrial fibrillation Am J Cardiol., 140 (2021), pp. 62-68 View PDFView articleCrossRefGoogle Scholar
• C. Escobar, J. Martí-Almor, A. Pérez Cabeza, M.J. Martínez-Zapata Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis Rev Esp Cardiol., 72 (2019), pp. 305-316 View PDFView articleView in ScopusGoogle Scholar
• S.H. Hohnloser, E. Basic, M. Nabauer Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: Insights from a large German claims database Clin Res Cardiol., 108 (2019), pp. 1042-1052 View at publisher Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
• J.C. Cowan, J. Wu, M. Hall, A. Orlowski, R.M. West, C.P. Gale A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation Eur Heart J., 39 (2018), pp. 2975-2983 View at publisher This article is free to access. CrossRefGoogle Scholar
• T. Forslund, J.J. Komen, M. Andersen, B. Wettermark, M. von Euler, A.K. Mantel-Teeuwisse, et al. Improved stroke prevention in atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants Stroke., 49 (2018), pp. 2122-2128 View at publisher CrossRefView in ScopusGoogle Scholar
• A.P. Maggioni, L. Dondi, F. Andreotti, A. Pedrini, S. Calabria, G. Ronconi, et al. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people Am Heart J., 220 (2020), pp. 12-19 View PDFView articleView in ScopusGoogle Scholar
• C. Escobar Cervantes, J. Martí-Almor, A.I.P. Cabeza, K. Bowrin, A. Llorac Moix, M. Genís Gironès, et al. Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain PLoS One., 17 (2022), p. e0266658 View at publisher CrossRefGoogle Scholar
• G. Barón Esquivias, G. Escolar Albaladejo, J.L. Zamorano, L. Betegón Nicolás, C. Canal Fontcuberta, M. de Salas-Cansado, et al. Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no valvular en España Rev Esp Cardiol., 68 (2015), pp. 680-690 View PDFView articleView in ScopusGoogle Scholar
• G. Restovic, D. Carcedo, E.J. McLeod, A.L.G. Guillermin, T. Evers Cost-effectiveness of rivaroxaban versus acenocumarol in the stroke prevention in patients with non-valvular atrial fibrillation in the Spanish setting Value in Health., 15 (2012), p. A375 View PDFView articleGoogle Scholar
• J.R. González-Juanatey, J. Álvarez-Sabin, J.M. Lobos, A. Martínez-Rubio, J.C. Reverter, I. Oyagüez, et al. Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España Rev Esp Cardiol., 65 (2012), pp. 901-910 View PDFView articleView in ScopusGoogle Scholar
• R. Noviyani, S. Youngkong, S. Nathisuwan, B.S. Bagepally, U. Chaikledkaew, N. Chaiyakunapruk, et al. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: A systematic review and meta-analysis BMJ Evid Based Med., 27 (2022), pp. 215-223 View at publisher CrossRefView in ScopusGoogle Scholar
• J. Polo García, D. Vargas Ortega, F. Formiga, I. Unzueta, S. Fernández de Cabo, J. Chaves Perfil de los pacientes con fibrilación auricular no valvular y riesgo moderado-alto de accidente cerebrovascular que no reciben anticoagulación oral en España Semergen., 45 (2019), pp. 396-405 View PDFView articleView in ScopusGoogle Scholar
• M. De la Figuera, M.A. Prieto, N. Marín, I. Egocheaga, S. Cinza Diferencias en el manejo de los pacientes con fibrilación auricular según inicie el tratamiento con anticoagulantes orales de acción directa el médico de atención primaria o el especialista. Estudios SILVER-AP y BRONCE-AP Semergen., 44 (2018), pp. 323-334 View PDFView articleView in ScopusGoogle Scholar
• J. Precioso, M. Larré, F.M. Navarro, Y.A. Silvero, L. Garrido, J.L. Llisterri Grado de control y cumplimiento terapéutico de la anticoagulación con acenocumarol en atención primaria Semergen., 42 (2016), pp. 363-369 Google Scholar
• J.M. Lobos, J. Polo, D. Vargas El médico de familia ante las barreras en la prescripción de los nuevos anticoagulantes orales: heterogeneidad, inequidad y confusión. Posicionamiento de las Sociedades Científicas de Atención Primaria en España Semergen., 46 (2014), pp. 1-3 Google Scholar
• I. Roldán, F. Marín, Cardiovascular Thrombosis Group of the Spanish Society of Cardiology and the proposal development Committee; Spanish Society of Cardiology (SEC); Spanish Thrombosis and Hemostasis Society (SETH); Spanish Society of Neurology (SEN); Spanish Society of Emergency Medicine (SEMES); Spanish Society of Internal Medicine (SEMI); Spanish Society of Primary Care Physicians (SEMERGEN) On the way to a better use of anticoagulants in nonvalvular atrial fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013 Rev Esp Cardiol (Engl Ed)., 69 (2016), pp. 551-553 View PDFView articleView in ScopusGoogle Scholar
• M. Anguita, A. Dávalos, E. López de Sá, J. Mateo, M. Monreal, J. Oliva, et al. Anticoagulantes orales directos en la fibrilación auricular no valvular: cómo mejorar su uso en España Semergen., 45 (2019), pp. 109-116 View PDFView articleView in ScopusGoogle Scholar
• A.J. Camm, P. Amarenco, S. Haas, S. Hess, P. Kirchhof, S. Kuhls, et al. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation Eur Heart J., 37 (2016), pp. 1145-1153 View at publisher This article is free to access. CrossRefView in ScopusGoogle Scholar
• S. Raposeiras-Roubín, D. Alonso Rodríguez, S.J. Camacho Freire, E. Abu-Assi, R. Cobas-Paz, C. Rodríguez Pascual, et al. Vitamin K antagonists and direct oral anticoagulants in nonagenarian patients with atrial fibrillation J Am Med Dir Assoc., 21 (2020), pp. 367-373.e1 View PDFView articleView in ScopusGoogle Scholar